share_log

Editas Medicine shares are trading lower after Morgan Stanley maintained an Underweight rating on the stock and lowered its price target from $17 to $15.

Editas Medicine shares are trading lower after Morgan Stanley maintained an Underweight rating on the stock and lowered its price target from $17 to $15.

在摩根士丹利維持對該股的減持評級並將其目標價從17美元下調至15美元后,Editas Medicine的股價下跌。
Benzinga ·  2022/05/09 10:56

Editas Medicine shares are trading lower after Morgan Stanley maintained an Underweight rating on the stock and lowered its price target from $17 to $15.

在摩根士丹利維持對該股的減持評級並將其目標價從17美元下調至15美元后,Editas Medicine的股價下跌。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論